Fingerprint
Dive into the research topics of 'FIGHT-302: First-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
FIGHT-302: First-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
Tanios S. Bekaii-Saab, Juan W. Valle, Eric Van Cutsem, Lorenza Rimassa, Junji Furuse, Tatsuya Ioka, Davide Melisi, Teresa MacArulla, John Bridgewater, Harpreet Wasan, Mitesh J. Borad, Ghassan K. Abou-Alfa, Ping Jiang, Christine F. Lihou, Huiling Zhen, Ekaterine Asatiani, Luis Féliz, Arndt Vogel
Research output: Contribution to journal › Review article › peer-review
9
Scopus
citations